-
Citi Upgrades Alkermes (ALKS) to Buy
-
Notable Analyst Rating Changes 1/21: (FIT) (ZFGN) (SPWR) Upgraded; (ERIC) (ALKS) (OIS) Downgraded
-
Notable Analyst Rating Changes 9/1: (SGMS) (BLOX) (VMW) Upgraded; (PTEN) (VRTS) (ENDP) Downgraded
-
Three Small Cap Biotech Stocks Added to Citi's Most Preferred List (ATRA) (NVAX) (PBYI)
-
Citi Downgrades Alkermes (ALKS) to Neutral
-
Notable Analyst Rating Changes 3/12: (AMRN) (WIN) (VRSK) Upgraded; (ALKS) (CNX) (MSI) Downgraded
-
Notable Analyst Rating Changes 05/29: (ADI) (ENOC) (SONS) Upgraded; (MXIM) (CMA) (BRCD) Downgraded
-
Citi Starts Alkermes (ALKS) at Buy
-
Alkermes (ALKS) Announces 13.9M Secondary Offering by Elan (ELN)
-
Unusual 11 Midday Movers 01/30: (GTXI) (ONCY) (PBY) Higher; (CTIC) (EMKR) (PMC) Lower
-
Morning Movers 01/30: (GTXI) (PBY) (TNB) (AMLN) Higher; (CTIC) (PMC) Lower
-
Trading Radar for 05/18: Target (TGT), Staples (SPLS), Deere & Co. (DE), Limited Brands (LTD), SodaStream (SODA) Report
-
Notable Mergers and Acquisitions of the Day 05/09: (HTZ)/(DTG) (ALKS)/(ELN) (NVDA)
-
Pre-Open Movers 5/9: (DTG) (BSFT) (ELN) Higher; (ZRAN) (SPLS) (C) Lower
-
Alkermes (ALKS), Elan (ELN) Enter $960M Stock-for-Stock Merger
-
Top 10 News Items for 10/18-10/22: Bank Concerns Remain Amid BofA's Bondholder Suit, Apple Still Top Dog, China Raises 1-Year Rates
-
Wave of Downgrades Hits Amylin, Alkermes, Eli Lilly (AMLN, ALKS, LLY)
-
Loeb's Third Point Q4 13F Breakdown: Ups Bets In Financials, Exits Large Pharma
-
Amlylin Pharma (AMLN): Upgraded to Buy at Citigroup; Street high target of $27
-
Morning Movers 3/31: AMLN, TBSI, FUQI, TXT, STSI Higher; TLCV, ACOR, ALTH, OXM, HIG Lower
-
Notable Analyst Rating Changes 12/19: ALKS, AIZ, ASML Upgraded; FLR, RIMM, EBAY Downgraded
-
Unusual 11 Mid-Day Movers 12/11: CEA, CRTX, DIOD, PDO Higher; GIL, EMKR, ISYS, HL Lower

